Moderna, Inc.
MRNANasdaq · SIC 2836
$61.82
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↑ +92.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$24.4B
Enterprise Value
$19.8B
P/E
—
P/S
11.0
P/B
3.3
EV/EBITDA
—
PEG
—
FCF Yield
-6.6%
Dividend Yield
—
Revenue (TTM)
$2.2B
Net Income (TTM)
-$3.2B
Free Cash Flow (TTM)
-$1.6B
Gross Margin
—
Operating Margin
-153.4%
Net Margin
-143.6%
ROE
-43.1%
ROIC
-96.5%
Debt / Equity
0.1
Net Cash
$4.6B
Return 1Y
+92.0%
Company profile
Moderna, Inc. develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The company has 44 development programs, which includes 26 in clinical trials across seven modalities.
- CEO
- Stéphane Bancel
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3,900
- Headquarters
- Massachusetts
- Website
- modernatx.com
Management & directors
- Hoge StephenPresident
- Mock James MChief Financial Officer
- Klinger Shannon ThymeChief Legal Officer
- Bancel StephaneChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-31
MRNA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$389.0M↑ +260.2%
Diluted EPS-$3.40↑ +34.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $803.0M | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$763.0M | $13.3B | $9.4B | -$4.2B | -$3.9B | -$3.1B |
| Net income | -$747.0M | $12.2B | $8.4B | -$4.7B | -$3.6B | -$2.8B |
| Diluted EPS | -$1.96 | $28.29 | $20.12 | -$12.33 | -$9.28 | -$7.26 |
| Operating cash flow | $2.0B | $13.6B | $5.0B | -$3.1B | -$3.0B | -$1.9B |
| Free cash flow | $2.0B | $13.3B | $4.6B | -$3.8B | -$4.1B | -$2.1B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -95.0% | 72.0% | 48.9% | -61.9% | -121.9% | -158.1% |
| Net margin | -93.0% | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $241.0M | $1.9B | $966.0M | $108.0M | $142.0M | $1.0B | $678.0M | $389.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.4B | -$70.0M | -$1.2B | -$1.1B | -$907.0M | -$260.0M | -$857.0M | -$1.4B |
| Net income | -$1.3B | $13.0M | -$1.1B | -$971.0M | -$825.0M | -$200.0M | -$826.0M | -$1.3B |
| Diluted EPS | -$3.33 | $0.03 | -$2.91 | -$2.52 | -$2.13 | -$0.51 | -$2.10 | -$3.40 |
| Operating cash flow | -$1.3B | -$1.6B | $825.0M | -$1.0B | -$919.0M | -$847.0M | $930.0M | -$630.0M |
| Free cash flow | -$1.5B | -$1.7B | $303.0M | -$1.2B | -$922.0M | -$880.0M | $891.0M | -$692.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -565.6% | -3.8% | -129.0% | -972.2% | -638.7% | -25.6% | -126.4% | -356.8% |
| Net margin | -530.7% | 0.7% | -115.9% | -899.1% | -581.0% | -19.7% | -121.8% | -345.2% |
Company news
Jul 17, 2026
- 3d agoModerna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?finance.yahoo.com
- 3d agoMRNA Advances Cancer Pipeline With New Immunotherapy Studyfinance.yahoo.com
- 3d agoNeglected Quant Safety Trade Makes a Comeback as AI Risks Risefinance.yahoo.com
- 3d agoArbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advancesbiopharmadive.com
Jul 16, 2026
- 4d agoABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?stocktwits.com
- 4d agoArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholdersfinance.yahoo.com
- 4d agoModerna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumorsfinance.yahoo.com
Jul 14, 2026
Jul 13, 2026
- 6d agoModerna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Notefinance.yahoo.com
- 7d agoWhat It Means To Hold Moderna Stock In A Crashtrefis.com
- 7d agoModerna, Takeda and Capricor on the verge of notching big drug approvalspharmavoice.com
- 7d agoUS Stock Market Today: S&P 500 Futures Rise As Inflation Cools And Earnings Loomfinance.yahoo.com
Jul 10, 2026
- 9d agoStock Market Today: Dow Ends Higher; SK Hynix Jumps In U.S. Trading Debut; Moderna Tumblesfinance.yahoo.com
- 9d agoUpdate: US Equity Indexes Rise as Diplomatic Engagements Between Washington, Iran Send Crude Oil Lowerfinance.yahoo.com
- 9d agoUpdate: US Equities Rise, Oil Prices Ease as Trump Confirms Iran Talksfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Hoge Stephen· President | Sale | 53,336 | $67.60 | $3.6M | filing |
| 2026-07-15 | Hoge Stephen· President | Option exercise | 37,226 | $19.15 | $712,877.90 | filing |
| 2026-07-15 | Hoge Stephen· President | Option exercise | 16,110 | $19.15 | $308,506.50 | filing |
| 2026-07-02 | Mock James M· Chief Financial Officer | Tax withholding | 703 | $72.50 | $50,967.50 | filing |
| 2026-07-02 | Mock James M· Chief Financial Officer | Option exercise | 1,452 | — | — | filing |
| 2026-06-15 | Hoge Stephen· President | Sale | 53,336 | $51.37 | $2.7M | filing |
| 2026-06-15 | Hoge Stephen· President | Option exercise | 37,226 | $19.15 | $712,877.90 | filing |
| 2026-06-15 | Hoge Stephen· President | Option exercise | 16,110 | $19.15 | $308,506.50 | filing |
| 2026-06-05 | Klinger Shannon Thyme· Chief Legal Officer | Tax withholding | 5,705 | $51.59 | $294,320.95 | filing |
| 2026-06-05 | Mock James M· Chief Financial Officer | Tax withholding | 5,705 | $51.59 | $294,320.95 | filing |
| 2026-06-05 | Klinger Shannon Thyme· Chief Legal Officer | Option exercise | 11,798 | — | — | filing |
| 2026-06-05 | Mock James M· Chief Financial Officer | Option exercise | 11,798 | — | — | filing |
| 2026-06-04 | Klinger Shannon Thyme· Chief Legal Officer | Sale | 3,471 | $50.00 | $173,550.00 | filing |
| 2026-06-04 | Klinger Shannon Thyme· Chief Legal Officer | Option exercise | 3,471 | $30.96 | $107,462.16 | filing |
| 2026-06-01 | Hoge Stephen· President | Tax withholding | 4,488 | $47.19 | $211,788.72 | filing |
| 2026-06-01 | Mock James M· Chief Financial Officer | Tax withholding | 1,197 | $47.19 | $56,486.43 | filing |
| 2026-06-01 | Klinger Shannon Thyme· Chief Legal Officer | Tax withholding | 1,047 | $47.19 | $49,407.93 | filing |
| 2026-06-01 | Klinger Shannon Thyme· Chief Legal Officer | Option exercise | 2,165 | — | — | filing |
| 2026-06-01 | Hoge Stephen· President | Option exercise | 9,282 | — | — | filing |
| 2026-06-01 | Mock James M· Chief Financial Officer | Option exercise | 2,475 | — | — | filing |
| 2026-05-28 | Hoge Stephen· President | Tax withholding | 295 | $47.61 | $14,044.95 | filing |
| 2026-05-28 | Mock James M· Chief Financial Officer | Tax withholding | 159 | $47.61 | $7,569.99 | filing |
| 2026-05-28 | Klinger Shannon Thyme· Chief Legal Officer | Tax withholding | 159 | $47.61 | $7,569.99 | filing |
| 2026-05-28 | Klinger Shannon Thyme· Chief Legal Officer | Option exercise | 328 | — | — | filing |
| 2026-05-28 | Hoge Stephen· President | Option exercise | 610 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.